Category Archives: Psychedelics

Microdosing has become something of a wellness trend in recent years, gathering traction in Australia and overseas.

The practice involves taking a low dose of a psychedelic drug to enhance performance, or reduce stress and anxiety.

While the anecdotal accounts are compelling, significant questions remain around how microdosing works, and how much of the reported benefits are due to pharmacological effects, rather than participants beliefs and expectations.

Weve just published a new study following on from two earlier studies on microdosing. Our body of research tells us some benefits of microdosing may be comparable to other wellness activities such as yoga.

Its not clear how many Australians microdose, but the proportion of Australian adults who have used psychedelics in their lifetime increased from 8% in 2001 to 10.9% in 2019.

After a slow start, Australian research on psychedelics is now progressing rapidly. One area of particular interest is the science of microdosing.

In an earlier study by one of us (Vince Polito), levels of depression and stress decreased after a six-week period of microdosing. Further, participants reported less mind wandering, which might suggest microdosing leads to improved cognitive performance.

However, this study also found an increase in neuroticism. People who score highly on this dimension of personality experience unpleasant emotions more frequently, and tend to be more susceptible to depression and anxiety. This was a puzzling finding and didnt seem to fit with the rest of the results.

Read more: Does microdosing improve your mood and performance? Here's what the research says

In a recent study, Stephen Brights research team recruited 339 participants who had engaged in either microdosing, yoga, both or neither.

Yoga practitioners reported higher levels of stress and anxiety than those in the microdosing or control groups (participants who did neither yoga nor microdosing). Meanwhile, people who had practised microdosing reported higher levels of depression.

We cant say for sure why we saw these results, although its possible people experiencing stress and anxiety were attracted to yoga, whereas people experiencing depression tended more towards microdosing. This was a cross-sectional study, so participants were observed in their chosen activity, rather than assigned to a particular group.

But importantly, the yoga group and the microdosing group recorded similarly higher overall psychological well-being scores compared with the control group.

And interestingly, people who engaged in both yoga and microdosing reported lower levels of depression, anxiety and stress. This suggests microdosing and yoga could have synergistic effects.

Through a collaboration between Edith Cowan University, Macquarie University and the University of Gttingen in Germany, our most recent study aimed to extend these findings, and in particular try to get to the bottom of the possible effects of microdosing on neuroticism.

We recruited 76 experienced microdosers who completed a survey before undertaking a period of microdosing. Some 24 of these participants agreed to complete a follow-up survey four weeks later.

The results were published in the Journal of Psychedelic Studies this month. We found that like our earlier work, the 24 participants experienced personality changes after a period of microdosing. But the changes were not entirely what we anticipated.

This time, we found a decrease in neuroticism and an increase in conscientiousness (people who are highly conscientious tend to be diligent, for example). Interestingly, a greater amount of experience with microdosing was associated with lower levels of neuroticism among the 76 participants.

These results are more consistent with other research on the reported effects of microdosing and high-dose psychedelics.

Read more: It's not all in your mind: how meditation affects the brain to help you stress less

Our most recent findings suggest the positive effects of microdosing on psychological well-being could be due to a reduction in neuroticism. And the self-reported improvements in performance, which weve also observed in our past research, could be due to increased conscientiousness.

When considered together, the findings of our research suggest contemplative practices such as yoga might be particularly helpful for less experienced microdosers in managing negative side effects such as anxiety.

However, we cannot know for certain if the changes weve observed are due to microdosers holding positive expectations because of glowing anecdotal reports theyve seen in the media. This represents a key limitation of our research.

As psychedelic drugs are illegal, its ethically complex to provide them to research participants we generally have to observe them taking their own drugs. So another key challenge of this research is the fact we cant know for sure precisely what drugs people are using, as they dont always know themselves (especially for LSD).

Given the illegal drug market is unregulated, theres a danger people could inadvertently consume a potentially dangerous new psychoactive substance, such as 25-I-NBOMe, which has been passed off as LSD.

People also cant be sure of the size of the dose theyre taking. This could lead to unwanted effects, such as tripping balls at work.

Potential harms like these can be mitigated by checking your drugs (you can buy at-home test kits) and always starting off with a much lower dose than you think you need when using a batch for the first time.

Despite the hype around microdosing, the scientific results so far are mixed. Weve found microdosers report significant benefits. But its unclear how much of this is driven by placebo effects and expectations.

For people who choose to microdose, also engaging in contemplative practices such as yoga might mitigate some of the unwanted effects and lead to better outcomes overall. Some people might find they get the same benefit from the contemplative practices alone, which is less risky than microdosing.

As a next step, one of us (Vince Polito) and colleagues are using neuroimaging to investigate the effect of microdosing on the brain.

If you practise microdosing, are based in Sydney, and are interested in taking part in this research, please email sydneymdstudy@gmail.com.

Read more: 'Microdosers' of psychedelics report improved mood, focus and creativity

Read the rest here:

Could microdosing be as good as yoga for your mood? It's not that big a stretch - The Conversation AU

Working with artists such as Jafaris, Nealo, Soul, FLYNN and Mango X Mathman to name a few; Emijis knack for sonic versatility has no limits.

The ambient debut album from neo-classical producer/composer Emiji landed last Friday, March 26th, and the timing was undeniably apt. A project designed to cleanse the mental palette of those struggling during a chaotic era; My Journeys also delves deep into the mindscape of the creative, showcasing emotions at their most potent from Emijis childhood to the present day. The album also challenges perceptions of psychedelic drugs for therapeutic reasons, exploring the potential for psychedelics to guide those who experience them substantially closer to nature.

Originally from Poland, Marcin Ciszczon is the co-founder of one of Ireland's most successful independent production houses, Diffusion Lab. After spending nearly a decade working with some of Irelands most exciting musical talents in his role of producer, composer and engineer, the time has come for his own music to be shared.

Having first moved to Ireland back in 2005, Marcin later returned after a five-year stint in his homeland in 2015 and started Diffusion Lab alongside Chris Bubenzer and Ivan Klucka. The hip-hop, pop and R&B juggernaut helped shape the likes of Hare Squead and Soul from the beginning of their careers. Emiji used every minute of spare down-time to craft his debut album, designing My Journeys as a soundscape for meditation, breathwork or progressive relaxation exercises.

I started the album back in 2017, and finally finished it last year during COVID, Marcin tells Hot Press about the contemporary project.

The concept of the album was to portray my personal experiences with mental health and holistic medicine, which meant I was reluctant to receive any feedback. Ive made it this way on purpose, and I totally understand that its niche music, so not everybody will appreciate the sound - and thats fine! Its my unique story, and the reasons why Ive made My Journeys matter just as much as the music itself.

The moving cinematic overture examines the depths of the human psyche, considering the profound themes of natures healing power and childhood wounds. A symphony of moving tracks; each song embodies aspects of pain, uncertainty, darkness and the human spirits inner workings. Emiji utilises a newfound understanding of the world to encourage others to dive into their own potential.

In 2017, I became a bit exhausted both mentally and physically, Marcin says. Psychedelics were suggested to me, so I decided to give LSD a try. I read about the dangers and side effects of using psychedelic drugs for mental health purposes from various articles and forums. I spent four months researching what to expect; discovering that a transformative, spiritual experience requires higher doses.

The Misuse of Drugs Act 1977, the Misuse of Drugs Act 1984, Misuse of Drugs Act 2015 and the Criminal Justice (Psychoactive Substances) Act 2010 regulate drug usage in Ireland, while the Controlled Substances Act (CSA) of 1970 classified all psychedelic drugs in the US as Schedule I. However, before the 70s, psychedelics were of keen interest to many psychiatrists and psychologists. Dozens of research studies with thousands of patients were completed using LSD and psilocybin with promising results and evidence which entirely conflicted with the restrictive laws.

Psychedelic research began again in the early 2000s to investigate the safety and uses of psychedelic drugs in substance use and mental health treatment. MDMA, LSD, psilocybin (the active compound in magic mushrooms), ibogaine and ayahuasca are all currently being researched for their potential in treating depression, PTSD, anxiety, OCD, substance abuse, addictions and more. Psychedelic drugs are also being evaluated as treatments for Alzheimers disease and other neurodegenerative diseases.

I felt like I was torn apart when I tried LSD and psilocybin, both who I was as a person and my internal values, Emiji says, reflecting on his own experiences.

Psychedelics showed me what I needed to do with my life. If youre not scared, they will show you the issues holding you back, as long as you arent resistant, Marcin adds. I was terrified at the beginning, but you have to go with the flow. I believe that if you know how to take the right dose, in the right environment, with the right people, then it can be relatively safe. The end goal is ego death, where it legitimately feels as though youre dying - but you come back. I trusted the people who guided me, they were experienced and knew that they were doing.

President Nixon criminalised psychedelics in the 1970s, and derailed research projects into their potential for mental health, but I believe that once you know what youre doing dosage-wise and are using them for the right reasons, hallucinogenic drugs are totally harmless, Emiji says, reflectively.

The first time I used LSD for therapy, it was one of the most difficult, meaningful experiences of my life. It turned the way in which I saw the world on its head. Through psilocybin and ayahuasca, I discovered what I needed to do to reach my potential. Its one thing to gain knowledge, but its another thing to actually put what you know into practice to change your life. I became much closer to nature spiritually, Maybe it is why I live in the countryside right now - surrounded by lakes and forest.

Outside of their use as treatments in clinical populations, psychedelics have been found to enhance self-acceptance, increase openness and improve social relationships. Emijis own relationship was strengthened as a result.

If you use psychedelics alone, youll experience a lot of beauty and darkness. Its like a total disconnection from the matrix but a connection to something bigger than all of us. If you have the experience with someone else, as I did with my girlfriend, it gives the effect of becoming at one with that person. At least it was like that for us, but every psychedelic experience is different.

A group of people in the Dublin area are undergoing trials to assess the effectiveness of the active ingredient of magic mushrooms in the treatment of severe depression, marking the first time a psilocybin-centred trial has occurred in Ireland. It remains an illegal drug for recreational purposes and its use in the Irish study - based out of Tallaght hospital - is heavily regulated.

I believe that psychologists undertaking the trial need to try psychotropic plants themselves to truly understand, but Im delighted that the trial is happening. There are dozens more going ahead in the US and in the UK. Psychedelics have the ability to render those who experience them totally open when talking to a therapist.

In my experience, it changed my entire outlook, Marcin continues. I feel as though they work the opposite way to regular antidepressant medication. The experience is too intense to cope with on a regular basis, and they often aid addiction rather than cause it. I stopped drinking alcohol, even though I was a moderate drinker. Ive also transitioned to a more healthy eating and lifestyle in general that I believe happened as a side effect of using psychedelics and making the right decisions. I think governments are often afraid of public reaction, but there are signs of changes in societal thinking towards psychedelics.

Emijis potent examination of his inner psyche and emotional range bleeds into My Journeys. Minimal in instrumentation, the album relies mostly on a unique blend of complex synths and intricate piano melodies. Collaborating with Dublin folk/pop duo Hvmmingbyrd on lead singles Larimar and talented vocalist Sandra Maria on Unspoken; Emiji creates serene, all-consuming musical results.

Not every song on the album is about nature, but many of them were inspired by it. The forest itself is music, and always calms me down, Emiji says, smiling.

Dawning is about the morning. The idea was inspired by the Bray Head, when I was high up in the mountains. I was trying to emanate what the rising sun would sound like. The track gets bigger and brighter, as the morning does. Youre hit with the bliss of warmth. Helpless was completely electronic originally. I was experimenting from totally electronic music to cinematic acoustic. The song was purely beats, but I introduced orchestral sounds and they took over. I wanted to portray how I fell at the time, as if I had no power, even though externally I may have looked well. Wounded Child was written about the anger you feel as a child when you cant express it, allowing it to fester and grow over time.

A voyage of self-discovery, Emiji offers the project as a gift to those needing tranquility during a chaotic era in history. Stretching his creative limits and ailing his own mental health overtook his desire to create music for the mainstream ear.

I was still experimenting and editing the album early last year, Emiji says. From my work with Diffusion Lab, Im aware that this country listens to mostly pop, hip-hop, R&B. Much of that group wouldnt be interested in ambient music, but mental health is becoming an even more critical crisis on account of lockdown. The hope is that My Journeys will offer some sense of peace and broaden the horizons of contemporary music in Ireland. You wont be hearing it in a nightclub, though!

Stream the new album from Emiji below:

Read the original post:

'The story behind My Journeys matters as much as the music itself': Neoclassical artist Emiji on his debut LP and exploration of psychedelics for...

Silo Wellness Inc. (CSE: SILO), a wellness company in the psychedelics and functional mushroom marketplaces, is pleased to announce the appointment of beer, wine and spirits brand marketing and communications expert, Stuart Kirby, as Vice President of Marketing & Communications as well as cannabis and hemp industries expert, Peter Holzworth, as Vice President of Business Development.

I am delighted to welcome two very accomplished senior executives to key leadership positions with Silo Wellness, stated Douglas K. Gordon, Chief Executive Officer of Silo Wellness. With a decorated career in the adult beverage industry marketing some of the most iconic brands in the space, I look forward to Stuarts creativity in delivering and amplifying the Marley licensing agreement we have just recently announced. I am equally excited to welcome Peter, who has tremendous experience in the cannabis and hemp industries, and to having him replicate that success within the psychedelic and functional mushroom category.

Kirby has more than twenty five years of experience with integrated strategic communications, brand public relations and consumer lifestyle marketing. He has overseen the marketing and communications functions for some of the most successful companies in their respective industries, such as the worlds leading supplier of wine, E & J Gallo, two leading global PR firms, Edelman and Hill & Knowlton as well as the worlds leading adult beverage supplier, DIAGEO.

Anchored to the belief that with great opportunity comes an equal measure of responsibility, Kirby has led numerous corporate social responsibility efforts from environmental sustainability plans and global responsible consumption initiatives to cause-related marketing campaigns and humanitarian relief operations partnering with non-profit entities such as Amnesty International, Surfrider Foundation, Pan-American Development Foundation, USAID and Habitat for Humanity.

Throughout my career, I have had the great privilege of being entrusted as steward to some of the most iconic, lifestyle brands in the world. Marketing and publicizing the legacy of Bob Marley a man, musician and mystic that I have long admired may be one of the most exciting professional opportunities I have ever been responsible for, commented Kirby. I look forward to transforming this fast-moving industry with a brand that stands for one love and translating that universal vision to positively impact the communities and cultures we partner with.

A veteran of the capital markets, cannabis and hemp industries, Holzworth has specialized experience in mergers and acquisitions, big data, compliance and regulatory affairs as well as brand development. As Vice President of Business Development for Silo Wellness, he will introduce and scale the Marley-branded mushroom line to the world by establishing relationships with large-scale distributors in the nutraceutical, nutrition, smoke shop and big-box retail markets.

It is my great pleasure to be entrusted with the awesome responsibility of taking one of the most beloved brand names in the world and applying my experience from the cannabis industry to scale this business exponentially in the immediate future, exclaimed Holzworth. I look very much forward to assisting Silo Wellness to lead and expand market accessibility, domestically and abroad, to the functional and psychedelics mushroom category. Given my international contacts, global market experience and new business development acumen, I am here to fast-track Silos industry leadership position and to scale the Marley brand globally in short order.

Silo Wellness is also pleased to announce the appointment of Kenny Choi to the role of Corporate Secretary, effective immediately. The appointment of Mr. Choi follows the resignation of Mo Yang as the Corporate Secretary of Silo Wellness.

About Silo Wellness

The mission of Silo Wellness is to improve health and wellness by developing and introducing psychedelic medicine to reduce trauma and increase performance by destigmatizing the active compounds in psychedelics and innovating ease of administration and ingestion. Silo Wellness intends to introduce new, safe and affordable alternatives to current medicines by facilitating entry into new and emerging markets where psychedelics are legal by conducting ketamine and psilocybin wellness retreats and elsewhere by manufacturing and distributing functional mushrooms.

Since its inception, Silo Wellness activities have focused on: (1) development of psilocybin-free functional mushroom tinctures; (2) the development of the formulation of a psilocybin nasal spray in Jamaica; and (3) offering of Jamaican and Oregon psychedelic wellness retreats as well as the cultivation of psychedelic mushrooms in Jamaica. None of Silo Wellness products claim to cure or mitigate any physical or mental disease, symptoms, disorders or abnormalities.

For further information, please contact: http://www.SiloWellness.com

Media Relations: Stuart Kirby, VP of Marketing & Communications press@silowellness.com

Silo Wellness Investor Relations: (604) 343-2724 IR@silowellness.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains forward-looking information and forward-looking statements (collectively, forward-looking statements) within the meaning of the applicable Canadian securities legislation. Other than statements of historical fact, all statements are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as expects, or does not expect, is expected, anticipates or does not anticipate, plans, budget, scheduled, forecasts, estimates, believes or intends or variations of such words and phrases or stating that certain actions, events or results may or could, would, might or will be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the appointment of officers of Silo Wellness and the business plans of Silo Wellness. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties and the potential impact of COVID-19. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Continue reading here:

Silo Wellness Hires Two Veterans of Lifestyle Marketing and Cannabis Industry to Promote Marley Line of Functional & Psychedelic Mushroom Brand -...

VANCOUVER, British Columbia., March 29, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company is pleased to announce that it has been added to the Horizons Psychedelic Stock Index ETF (PSYK) in its first quarterly rebalance of holdings.

PSYK (PSYK: NEO) is the world's first ETF (Exchange Traded Fund) offering direct exposure to North American publicly listed securities that have significant business activities in, or significant exposure to, the psychedelics industry. The underlying index is the North American Psychedelic Stock Index, which is a proprietary index owned and operated by Horizons ETFs, and Solactive AG is the independent calculation agent for the index.

On February 1st, 2021, Algernon announced that it had established a clinical research program for the treatment of stroke focused on AP-188 (N,N-Dimethyltryptamine or DMT), a known psychedelic compound, said Christopher J. Moreau CEO of Algernon Pharmaceuticals. Being added to the PSYK is a reflection of the important work Algernon has undertaken with its DMT stroke research program and will help bring a further level of awareness to the Company among a wide range of investors.

About Horizons Psychedelic ETF and the North American Psychedelic Index

The Horizons Psychedelic ETF is the world's first exchange traded fund offering direct exposure to North American publicly listed securities that have significant business activities in, or significant exposure to, the psychedelics industry. Horizons ETFs Management (Canada) Inc. which manages the fund, is a global ETF provider with ETF solutions available to investors across the globe. Horizons ETFs have over $17.5 billion of assets under management and 88 ETFs listed on major Canadian stock exchanges.

The underlying index for the Horizons Psychedelic ETF is the North American Psychedelic Stock Index, which is a proprietary index owned and operated by Horizons ETFs, with Solactive AG being the independent calculation agent for the index. The Index, which rebalances each calendar quarter, has been designed to provide a measure of the performance of North American publicly listed life sciences companies focused on psychedelic medicines, and other companies with business activities in the psychedelics industry.

Story continues

DMT Background

N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. DMT occurs naturally in many plant species and animals and has been used in religious ceremonies as a traditional spiritual medicine by indigenous people in the Amazonian basin. DMT can also be synthesised in a laboratory.

At higher doses, DMT has a rapid onset, intense psychedelic effects, and a relatively short duration of action with an estimated half-life of less than fifteen minutes. Like other hallucinogens in the tryptamine family, DMT binds to serotonin receptors to produce euphoria and psychedelic effects. Because the effects of DMT do not last very long, it has been referred to in some circles as the businessmans trip.

Named the Spirit Molecule by Dr. Rick Strassman, an American clinical associate professor of psychiatry and DMT research pioneer, DMT has been shown to induce neuroplasticity in a number of key preclinical studies. DMT is believed to activate pathways involved with forming neuron connections and has been shown in studies to increase the number of dendritic spines on cortical neurons. Dendritic spines form synapses (connections) with other neurons and are a major site of molecular activity in the brain.

While Dr. Strassmans Phase 1 bolus intravenous human study identified the sub-hallucinogenic dose of DMT in humans, another preclinical animal study demonstrated this same dose level still retains the neuroplastic effect seen in higher hallucinogenic doses.

Algernon will be investigating an intravenous sub-psychedelic dose of DMT as a potential treatment for Stroke in its research and clinical studies.

Algernon has filed new provisional patents for new forms of DMT, in addition to formulation, dosage and method of use claims for ischemic stroke. The Company has also filed claims for combination therapy of DMT and constraint-induced movement therapy (CIMT).

About Algernon Pharmaceuticals Inc.

Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

CONTACT INFORMATION

Christopher J. MoreauCEOAlgernon Pharmaceuticals Inc.604.398.4175 ext 701

info@algernonpharmaceuticals.cominvestors@algernonpharmaceuticals.comwww.algernonpharmaceuticals.com.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as will, may, should, anticipate, expects and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Companys expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Read more here:

Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF - Yahoo Finance

Vancouver, British Columbia--(Newsfile Corp. - March 30, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) ("NeonMind"), a psychedelic drug development company, is pleased to announce that Robert Tessarolo, President & Chief Executive Officer, will be speaking at the Psychedelic, Therapeutics, & Drug Development Conference that will be held virtually from May 4-6. He will be speaking on the use of psychedelics in treating obesity and eating disorders.

Figure 1: NeonMind CEO Robert Tessarolo to Speak at the Psychedelic, Therapeutics, & Drug Development Conference

To view an enhanced version of Figure 1, please visit:https://orders.newsfilecorp.com/files/7646/78904_neon2.jpg

The conference will unite the top business and academic leaders including Frederick Barrett, Ph.D., Assistant Professor of Psychiatry & Behavioral Sciences at Johns Hopkins School of Medicine, to discuss, analyze, and share intelligence on regulatory changes and other challenges on psychedelic research for treatment of a myriad of serious chronic medical conditions.

"The Psychedelic, Therapeutics, and Drug Development Conference is an excellent opportunity for NeonMind to share our vision and progress with other industry leaders and key stakeholders," said Rob Tessarolo. "I also look forward to listening to the many great experts and innovators who will discuss a number of regulatory and policy changes that will help unlock the full health potential of this emerging field."

NeonMind is currently advancing two (2) psilocybin-based drug development programs aimed at treating obesity. Psychedelic therapy has the potential to institute long term positive behaviours that may aid in weight loss and its maintenance, and psilocybin in low doses may help control appetite and satiety.

"There is a clear need for new treatments, new solutions, new approaches for the obesity epidemic and psychedelics are well positioned to offer new therapeutic breakthroughs," said Rob Tessarolo. "NeonMind will continue to advance our important research and be a leader in commercialization following regulatory approval."

Story continues

About NeonMind Biosciences Inc.

NeonMind is engaged in research and development of products to optimize human health and performance. NeonMind has two divisions, a pharmaceutical division engaged in drug development of psychedelic compounds, and a consumer products division with a focus on mushroom infused products. NeonMind's consumer division currently sells 4 NeonMind branded coffee products in Canada through NeonMind's direct to consumer e-commerce platform, and it has plans to launch products in Canada as natural health products once Health Canada approves its recent applications. NeonMind also plans to launch dietary supplements in the United States this spring.

In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind's first drug candidate aims to use synthetic psilocybin to enhance a patient's ability to adopt behaviours that cause weight loss and maintain that loss through psychedelic-assisted cognitive therapy. The second drug candidate offers low dose synthetic psilocybin as a treatment to suppress appetite.

NeonMind's first drug candidate employs psilocybin as an agonist to the serotonin receptor 5- HT2A, which is involved in the hallucinogenic effect of psychedelics, and the second drug candidate employs low-dose psilocybin as an agonist to the 5-HT2C receptor, which controls appetite.

For more information on NeonMind, go to http://www.NeonMindBiosciences.com.

Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.rob@neonmind.com Tel: 416-750-3101

Investor Relations:Edge Communicationsinvest@neonmind.com Tel: 1-866-318-6874

Renmark Financial Communications Inc. Melanie Barbeaumbarbeau@renmarkfinancial.com Tel: 416-644-2020 or 212-812-7680

Media Inquiries:Exvera Communications Inc.brittany@exvera.com

The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind's future performance. The use of any of the words "could", "expect", "believe", "will", "projected","estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind's drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/78904

Original post:

NeonMind CEO Robert Tessarolo to Speak at the Psychedelic, Therapeutics, & Drug Development Conference - Yahoo Finance

NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream investor conferences, and investor LiveChats on social media streams. Over 160,000 investors have participated in Wall Street Reporters livestream events in the past 30 days.

Interactive Games Technologies (CSE: BETS) (OTC: BLITF), CEO Chris Neville: "Building Next Billion Dollar Global Betting Giant"

In a recent interview at Wall Street Reporters NEXT SUPER STOCK livestream, Interactive Games Technologies (OTC: BLITF) (CSE: BETS) CEO Chris Neville, shares his companys ambitious global strategy, with a unique focus on India. As a pioneer of online gaming with almost 20 year's experience, Neville sees a strong parallel between the poker boom of the early 2000s and the Indian market today.

Watch (CSE: BETS) (OTC: BLITF) NEXT SUPER STOCK Video: http://bit.ly/2Zuubon

India is one of the fastest growing online gaming markets in the world. With a growing population, especially the middle class, a burgeoning economy, the fastest internet adoption in the world, and with 65% of the population under the age of 35, India is the perfect storm for skill based online gaming.

Interactive Games Technologies (OTC: BLITF) (CSE: BETS) sees India as the perfect launchpad for its global betting business, with relatively low customer acquisition costs, less competition, and blue sky upside potential. By partnering with Indian social influencers such Bollywood celebrities and cricket stars, BLITF reaches their 150 million followers in India. BLITF is also expanding into new untapped global gaming markets such Canada which is about to legalize sports betting.

March 23 - BLITF reports that launch of its recently acquired skill-based fantasy gaming product, BLITZPOOLS, is exceeding expectations. BLITZPOOLS is already over 150,000 new registrations and expects to close the month with over 250,000 new players. It is clear the industry leading product and brand positioning is resonating with the Indian fantasy gaming audience, and is now one of Indias fastest-growing skill-based fantasy sports platforms.

Story continues

March 16 - BLITF announces plans to enter US gaming market. BLITF management is in talks with US land-based casino to partner in building and managing a digital gambling platform and offering. Morgan Stanley estimates that the U.S. online gambling market (sports betting and iGaming) will soon top $20 billion Gross Gaming Revenue per year. The lack of permissive online gambling regulations until recently in the U.S. means that online gambling experience is limited in the U.S. market. Online gambling has, however, been permitted in other countries and regions for over two decades. BLITF has assembled a team of online gambling executives, with over 100 years online gambling experience, and believes can provide land-based operators with the knowledge, experience and expertise to capitalise on the growing US online gambling market. BLITF CEO, Chris Neville said: The Company is hugely excited by this opportunity in the burgeoning U.S. online gambling market. We have a great team and a great partner to add significant value to future potential partners in this space.

March 8 - BLITF announces signing of rising cricket stars Ishan Kishan, Rahul Chahar, Shreyas Gopal and Wriddhiman Saha to be the face of the brand. Attracting their ever-growing and large fan base to the app, the cricketer quartet will be an integral part of the 360-degree digital and offline campaign activation of BLITZPOOLS. In addition to these cricket stars and as part of the new brand launch, BLITZPOOLS has engaged celebrities and influencers alike with a total follower count in excess of 215 million, the identities of which will be revealed at time of post and in a future release.

Watch (CSE: BETS) (OTC: BLITF) NEXT SUPER STOCK Video: http://bit.ly/2Zuubon

Hapbee Technologies (OTC: HAPBF) CEO Scott Donnell: Tech That Lets You Choose How you Feel = Billion Dollar Market OpportunityOne of the most unique companies to present at Wall Street Reporters NEXT SUPER STOCK livestream events in recent years, is Hapbee Technologies (OTC: HAPBF) which markets wearable tech that lets you choose feelings on demand. The patented technology uses low-power electromagnetic signals designed to produce sensations such as Happy, Alert, Focus, Relax, Calm and Sleepy. HAPBF is developing new feeling signals regularly which are available on a subscription basis through its mobile app.

In his interview with Wall Street Reporter, Hapbee CEO Scott Donnell explains how Hapbees technology platform addresses untapped multi-billion dollar market opportunities which include mental health, sleep, and fitness, among other aspects of our daily lives which are impacted by feelings. Scott also shares HAPBFs unique D2C e-commerce strategy which is based on proven systems of todays most successful billion-dollar D2C fitness, health and lifestyle brands. Hapbee is rapidly being embraced by influencers in fitness/wellness, biohackers, and high-performance executives who want to perform and feel their best. HAPBF unique technology positions it at the forefront of the fast growing $32 billion wearable tech market.

Watch Hapbee Technologies (OTC: HAPBF) NEXT SUPER STOCK Video: http://bit.ly/3vh6Ncx

ESE Entertainment (TSX.V: ESE) (OTC: ENTEF) CEO Konrad Wasiela: E-Sports M&A Pipeline With Over $100 million Annual Revenues

ESE Entertainment (TSX.V: ESE) (OTC: ENTEF) CEO Konrad Wasiela, a featured presenter at Wall Street Reporters NEXT SUPER STOCK investors livestream conference, recently updated investors on his goal of building ESE into a billions dollar global enterprise. Wasiela shared that ESE now has a growing M&A pipeline with over $100 million annual revenues and expected to close a significant number of these potential transactions in the coming months. ESEs stated goal is to build a global E-Sports business with a valuation of $1 Billion+.

Watch ESE (OTC: ENTEF) Next Super Stock livestream video: https://bit.ly/3qq59mb

In his interview with Wall Street Reporter, ESE CEO Konrad Wasiela, says the company is now ready to scale - expanding its global footprint, with new partnerships with global brands like Porsche, driving revenue growth with aggressive focus on top line sales and margin expansion, and M&A opportunities. ESE is now rapidly expanding, with multiple revenue streams including, E-Sports infrastructure software powering global tournaments, exclusive digital media distribution, broadcast rights, and owning world-class leagues and teams, including its K1CK global E-Sports franchise.

March 17 - ENTEF announces launch of Virtual Pitstop, a new business unit dedicated to simulation racing (sim racing). Virtual Pitstop will provide technology for video game developers, racing fans, and gamers to engage in motorsport related esports across the globe. ENTEF CEO Konrad Wasiela, commented, We are excited to announce the expansion of our digital Motorsport business with the launch of the Virtual Pitstop brand. Our past successful partnerships and business collaborations with Porsche, Kia, and Orlen are just the beginning. We see a significant opportunity to implement fast growing technology and monetization via AR/VR, NFTs, skins, and more.

Watch ESE (OTC: ENTEF) Next Super Stock livestream video: https://bit.ly/3qq59mb

Delic Holding (CSE: DELC) (OTC: DELCF) CEO Matt Stang: Psychedelics For Mental Health Is Major Growth Trend

In a recent interview at Wall Street Reporters Investors Discovery Day livestream, Delic Holdings (OTC: DELCF) CEO Matt Stang shared his unique strategy for capitalizing on what is expected to be the next massive new market opportunity: psychedelics. As the former publisher of High Times Magazine over 14 years, Matt Stang paved the way for cannabis legalization, and along the way, developed a network of industry pioneers who are now active in the psychedelics space. In his interview, Stang explains DELCFs unique psychedelics ecosystem business model - which offers synergies, and leverage - and generates revenues across the entire psychedelics value chain.

DELCFs ecosystem spans across an online media platform which provides consumers information and reviews, on psychedelics - an expanding chain of ketamine treatment clinics - to a licensed research lab developing innovative psychedelics product formulations - to clinical research data for biotech & pharma for developing new psychedelic compounds. DELCF intends to expand this ecosystem further, through M&A, leveraging Matt Stangs 14 years of experience and wide industry contacts across the industry.

Watch DELCF NEXT SUPER STOCK video: http://bit.ly/3uK4L4y

March 5 - DELCF announces acquisition of the Homestead brand and intellectual property. Homestead is a legacy counterculture distributor of psychedelic media and creator of one of the first self-contained mushroom grow kits. Matt Stang, Founder and CEO of DELCF commented, "The acquisition of Homestead is an exciting one for us at DELIC. It shows how we are increasing accessibility to this nascent industry within regulated jurisdictions. Homestead not only sold tens of thousands of mushroom kits globally but also was one of the earliest distributors for High Times and many other counter culture publications. We look forward to growing together and increasing shareholder value with what we accomplish."

February 25 - DELCF announces acquisition of Complex Biotech Discovery Ventures, a licensed psilocybin and cannabis research laboratory focused on extraction, analytical testing, and chemical process development. Founded by award-winning chemist, Dr. Markus Roggen, and UBC Professor, Glenn Sammis, CBDV supports the psychedelic industry with high precision chemical analytics and metabolomic identification.

Watch DELCF NEXT SUPER STOCK video: http://bit.ly/3uK4L4y

WALL STREET REPORTER

Wall Street Reporter (Est. 1843) is the leading financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. http://www.WallStreetReporter.com. Nothing in this news summary shall be construed as investment advice. Quotes/content may be edited for brevity and context. Full disclaimer, and relevant SEC 17B disclosures here: http://bit.ly/39kkE7K

About Wall Street Reporters Next Super Stock conference:

Wall Street Reporter's NEXT SUPER STOCK Live! conference is dedicated to featuring select companies that have near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead. Click here to join next livestream event: https://www.wallstreetreporter.com/next-superstock-online-investor-conference/

CONTACT:

WALL STREET REPORTER

(212) 871-2057 ext 7

http://www.WallStreetReporter.com

Here is the original post:

NEXT SUPER STOCKS On The Move: E-Sports, Psychedelics, iGaming, and FeelTech - CEOs of BLITF, ENTEF, HAPBF and DELCF, Positioning for Explosive...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (Cybin or the Company), a biotechnology company focused on progressing psychedelic therapeutics, today announced key senior management changes to lead the buildout of its development and clinical operations in the United States and Europe. Effective immediately, Alexander Belser, PhD, will serve as Chief Clinical Officer, and Aaron Bartlone will serve as Chief Operating Officer of Cybin US Holdings Inc. The Company also announced that co-founder and former Chief Operating Officer, Paul Glavine will assume the role of Chief Growth Officer of Cybin Inc., and co-founder and former SVP, Business Development, John Kanakis will assume the role of Chief Business Officer.

We are committed to building our presence both in the United States and in Europe to advance our mission of improving mental healthcare through therapeutic development programs and innovative drug delivery systems. These appointments will serve to strengthen our development and clinical operations globally and solidify Cybins position within the industry. Alex and Aaron bring deep clinical, commercial and regulatory expertise that will serve to broaden our management and scientific leadership teams. We look forward to their contributions as we pursue increased visibility across these additional markets, stated Doug Drysdale, Chief Executive Officer.

Paul and Johns extensive entrepreneurial experience was instrumental in shaping the initial formation of Cybin and the companys subsequent emergence as a leader within the psychedelics space. Their deep commitment to Cybins mission will continue as they assume these new roles and will allow them to further accelerate business development and investor awareness initiatives. We believe these appointments are an important step in taking Cybin to the next level, concluded Drysdale.

Mr. Bartlone is an accomplished biopharmaceutical executive with a proven track record across numerous therapeutic and functional areas, including quality assurance, regulatory affairs, product development, compliance, and commercial operations. Prior to joining Cybin, Mr. Bartlone was President & Managing Director at AB Dynamix LLC, where he was responsible for developing customized and innovative quality management systems, regulatory strategies, and supply chains for developing pharmaceutical, biotechnology, and medical device companies. Previously, Mr. Bartlone held positions of increasing responsibility at UCB Inc., a global pharmaceutical company, including Commercial President and Chief Quality, Patient Safety, Health Safety & Environment & Risk Officer. Mr. Bartlone has developed global teams of over 1,000 colleagues in 50 countries and has successfully driven over 25 small and large molecular therapies and drug-device combination products to the global marketplace. Mr. Bartlone has also held various director-level research, quality, regulatory, and managerial positions at Eli Lilly. Mr. Bartlone has a Bachelor of Science in Chemistry from Youngstown State University and a Master of Science in Analytical Chemistry from the University of Notre Dame.

Dr. Alexander Belser is a well-known leader in the field of psychedelic research, having served as an investigator on clinical trials of psilocybin and MDMA to treat depression, anxiety, substance use, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and end-of-life distress at New York University and Yale University. Dr. Belser previously served as Chief Clinical Officer at Adelia Therapeutics, where he directed the clinical program investigating tryptamines and phenethylamines for a variety of treatment indications. Dr. Belser is the founding President of Nautilus Sanctuary, the first non-profit center for psychedelic medicine in the eastern United States. Dr. Belser has taught widely on the topic of psychedelic medicine, having authored a dozen peer-reviewed publications and given over fifty lectures, presentations, and Grand Rounds on psychedelic topics. As a Clinical Research Fellow and Co-Investigator at Yale University, Dr. Belser investigated psychedelic treatments for major depression and for OCD. Dr. Belser has worked as a therapist on studies of MDMA-assisted psychotherapy for the treatment of severe PTSD. Dr. Belser trained at Bellevue Hospital, Mount Sinai Beth Israel Hospital, and New York Psychiatric Institute at Columbia University. Dr. Belser has also received extensive training in psychedelic psychotherapy from recognized senior teachers. Dr. Belser has Bachelor of Arts degrees in English and Government from Georgetown University, a Master of Arts in Philosophy from Cambridge University, and a PhD in Counseling Psychology from New York University.

About Cybin

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as may, should, could, intend, estimate, plan, anticipate, expect, believe or continue, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the development of the Companys operations and presence in the United States and Europe and the Companys advancement of therapeutic development programs and innovative drug delivery systems. There are numerous risks and uncertainties that could cause actual results and Cybins plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Cybin makes no medical, treatment or health benefit claims about Cybins proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybins performance and operations.

The NEO Exchange has neither approved nor disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.

See the rest here:

Cybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United States and Europe - Business Wire

Wikipedia list article

The following is a list of psychedelic drugs of various chemical classes, including both naturally occurring and synthetic compounds. Serotonergic psychedelics are usually considered the "classical" psychedelics[dubious discuss], whereas the other classes are often seen as having only secondary psychedelic properties; nonetheless all of the compounds listed here are considered psychoactive and hallucinogenic in humans to some degree.

Some of these compounds may be classified differently or under more than one category due to a unique structural classification, multiple mechanisms of action, or the fact that the precise pharmacodynamic actions of the compound are not yet completely understood. Because of the vast amount of possible substitutions and chemical analogs of most psychedelic compounds, the total diversity of chemical compounds which produce psychedelic effects in humans is not fully reflected within this list, leaving room for many that have not yet been sufficiently investigated and others that have not yet been discovered.

Naturally occurring compounds are marked with a .

Link:

List of psychedelic drugs - Wikipedia

Timothy Learys dead.

The Moody Blues, 1968

Psychedelics derived from plants have been used in religious ceremonies for centuries, and in 1938, the first synthetic psychedelic, lysergic acid diethylamide (LSD), was synthesised by the Swiss chemist Albert Hoffman. By 1947, LSD was marketed as a psychotherapy medication, and in 1960, Harvard psychologist Timothy Leary began popularising LSD and psilocybin, the hallucinogenic compound in magic mushrooms, as mind-altering therapeutics. However, by the mid-1960s, amidst growing concerns in the U.S. and Europe about the illicit production of LSD and its growing use for recreational purposes in the absence of medical supervision, the U.S. Congress passed the Drug Abuse Control Amendments, making it a misdemeanour to manufacture or sell LSD without a license. By 1970, psychedelic research was largely halted by the passage of the Controlled Substances Act of the Comprehensive Drug Abuse Prevention and Control Act in the U.S. and similar legislation in Europe. Timothy Learys vision for psychedelics indeed seemed dead, as foretold by Ray Thomas of the Moody Blues.

However, over the past decade, a resurgence of clinical research has shifted perceptions that psychedelics are neurotoxic substances to potential therapeutics for psychiatric disorders. Globally, psychiatric disorders are a major public health problem, affecting approximately 350 million people, many of whom do not respond to conventional treatment. Recent clinical evidence suggests psychedelics can help these patients.

Psychedelics are chemicals that alter ones perception of reality by modulating how nerve cells in the brain communicate with each other. In addition to LSD and psilocybin, psychedelics include ketamine, 3,4-methylenedioxymethamphetamine, also known as MDMA or ecstasy, and phytocannabinoids, the psychoactive chemicals in marijuana. The U.S. Drug Enforcement Agency (DEA) classifies these drugs according to their potential for abuse: LSD, psilocybin, MDMA, and delta-9-tetrahydrocannabinol (9-THC), a psychoactive phytocannabinoid in marijuana, are classified as schedule I controlled substances with no currently accepted medical use and a high potential for abuse. Ketamine is classified as a schedule III controlled substance with moderate to low potential for physical and psychological dependence.

These drugs can also be classified according to their psychoactive effects. LSD, psilocybin and MDMA are hallucinogens. MDMA also has stimulant properties, meaning it can elevate mood and increase alertness and energy. Simulants are often highly addictive and can cause paranoia over time. Ketamine is a dissociative anaesthetic, defined as distorting sensory perceptions and causing feelings of disconnection or detachment. Counterintuitively, at lower doses, ketamine can act as an empathogen, promoting feelings of sympathy and empathy. 9-THC in marijuana has hallucinogenic, stimulant and depressive actions.

Chronic use or high-dose acute exposure to psychedelics can be neurotoxic, causing addiction, paranoia, panic attacks, high blood pressure and, in severe cases, loss of consciousness and seizures. Both human and animal studies demonstrate that toxic exposures to psychdelic drugs can change the structure and function of the brain, possibly by causing excessive or overstimulation, oxidative stress or neuroinflammation. The developing brain is especially vulnerable to the neurotoxic effects of these drugs, because they can disrupt the normal pattern of connections made between brain cells during brain development. Children exposed to psychedelic drugs during pregnancy or breast-feeding have an increased risk of developing psychiatric disorders.

Recent clinical studies suggest that psilocybin, MDMA, ketamine and phytocannabinoids can reduce depression and anxiety in patients who do not response to conventional treatment. MDMA and psilocybin have been designated by the U.S. Food and Drug Administration as breakthrough therapies for posttraumatic stress disorder (PTSD) and treatment-resistant depression, respectively. MDMA shows promise as a treatment for social anxiety in autistic adults and psilocybin, for cancer-related anxiety. A single, subanesthetic dose of ketamine in addition to psychotherapy can rapidly improve symptoms in patients with a major depressive disorder for up to 7 days. While preliminary, research supports the use of LSD in the treatment of psychiatric disorders. Clinical data suggest psychedelic drugs may also be effective in treating substance abuse disorders, end-of-life psychiatric distress, and suicide ideation. Marijuana, and in particular the phytocannabinoid cannabidiol (CBD), can reduce pain and relieve anxiety. In addition CBD has been approved for treatment-resistant seizure disorders.

It is not clear yet how psychedelics work as therapeutics, but emerging data suggests these drugs protect against atrophy of neurons and promote outgrowth of neurites, the processes extended by neurons that determine how neurons connect with each other. Notably, neurites are diminished in many treatment-resistant psychiatric disorders. Psychedelic drugs are not being used as stand-alone drug treatments, but rather they are used on one or a few occasions during psychotherapy sessions to overcome obstacles to successful psychotherapy and to boost the therapeutic experience. It is theorised that the experience itself, rather than simply the pharmacological effects of the drug, leads to cure or sustained remission of severe, treatment-resistant psychiatric disorders.

Due in part to clinical studies documenting the therapeutic potential of psychedelics, 37 states in the U.S. have legalised the use of medical cannabis and cities in Colorado, California, and Massachusetts have decriminalised psilocybin. Oregons Measure 110 decriminalised the possession of small amounts of psychedelic drugs and increased access for medical uses. While the regulation and perception of psychedelics is changing, this should not be interpreted as meaning these drugs are considered safe. Indeed, the Sacramento County District Attorneys Laboratory of Forensic Services reports cannabis and stimulants are among the most commonly reported substances of abuse in cases of driving under the influence of drugs (DUID) and drug seizures. Additional safety studies to determine the long-term effects of the therapeutic use of psychedelics are needed to support their clinical use. These limitations notwithstanding, the preliminary clinical data on the therapeutic potential of psychedelic drugs warrant further research, with particular focus on synthesising derivatives of these compounds that retain therapeutic effects while eliminating addictive and neurotoxic effects.

Please note: This is a commercial profile

Editor's Recommended Articles

More:

The changing perspective of psychedelic drugs with a history of abuse - Open Access Government

As psychedelics gain ground as a potential therapy for mental health disorders, there remains a pressing concern that patients in clinical trials may have adverse effects to the drugs.

New research identifies personality traits that have been associated with positive and negative experiences on psychedelics in previous studies, information that could help predict how future clinical trial participants will respond to the drugs.

The findings suggest that people more open to new experiences and willing to surrender to the unknown may be best positioned to have a positive experience on psychedelics, and individuals who tend to be preoccupied or apprehensive could be more likely to have a negative, or challenging, experience.

These predictions could be used by scientists to help hesitant clinical trial patients feel more open to the potential therapy, possibly by offering lower doses as a starting point, researchers say though such a concept remains speculative.

The findings point to interesting testable things we can look at in future research, saidAlan Davis, assistant professor ofsocial work at The Ohio State University and senior author of the review. It might be plausible to use threshold doses that are smaller than those used in a trial as a first exposure so people have less anxiety, experience the benefit and, from that, go into a higher dose later.

The study is published online in the journal ACS Pharmacology & Translational Science.

To arrive at these predictions, the researchers reviewed 14 published clinical trials and other types of studies conducted in recent years that documented participants personality traits or states of mind and their associations with a positive or negative experience on psychedelics.

Its been an open question so far in psychedelic science: How can we predict how people will react? We thought this review would be a good opportunity to develop a narrative of what the consensus is so far, said study first author Jacob Aday, a PhD candidate in psychology at Central Michigan University who collaborates with Davis.

Preliminary evidence has suggested that psychedelics may be effective in treating mood, anxiety, trauma-based and substance use disorders.

Psychedelics might broadly apply to a whole range of different psychiatric problems, and in part that might be because theyre directly affecting neurotransmission and the brains ability to communicate in new ways that involve different parts of the brain, Davis said. But there is still a lot to unpack about exactly how this all works and why it may be effective.

Of the studies reviewed, 10 tested psilocybin (commonly known as magic mushrooms) as a therapy, two involved LSD, one used a hallucinogenic brew called ayahuasca and one examined psychedelic use in general.

Experiences on psychedelics vary in intensity and tend to comprise three categories: a mystical, insightful or challenging experience. A mystical experience can feel like a spiritual connection to the divine, an insightful experience increases peoples awareness and understanding about themselves, and a challenging experience relates to emotional and physical reactions such as anxiety or increased arousal.

The review suggests that people who are high in the traits of openness, acceptance and absorption the tendency to immerse oneself into imaginative experiences and in a psychological state of surrendering to whatever may transpire are more likely to have positive psychedelic experiences.

A state of surrender, in particular, stood out for its association with a lower chance for acute dread and a higher likelihood of a mystical experience and what is known as ego dissolution, when ones sense of self gives way to a closer connection to other people and the broader world.

In contrast, people who are low in those traits or who are in preoccupied, apprehensive or confused states are considered more likely to experience adverse reactions.

There was also tentative evidence that increased experience with psychedelics and increased age were associated with slightly less intense effects with the drugs, Aday said. And there werent any differences according to sex. Men and women responded similarly.

Three studies had identified potential neurological markers that could help predict research participant reactions to psychedelics, but the cost of collecting brain scans to screen trial candidates made them less practical predictors than psychological traits, Aday said.

Davis has already considered potential reactions to psychedelics for a psilocybin trial he is planning for veterans who have post-traumatic stress disorder.

People who have experienced trauma are not very high in surrender, because they are anxious all the time about their past traumatic experiences, he said. A possibility to explore is starting with a low or moderate dose prior to giving the full therapeutic dose, which might help them increase in surrender. Weve designed the study this way, thinking that might be helpful.

Study co-authors include Cayla Mitzkovitz, Emily Bloesch and Christopher Davoli of Central Michigan University.

Here is the original post:

Predicting who may do best with psychedelic-assisted therapy - The Ohio State University News